ArticleJournal of animal science2026
Determination of the relative bioavailability of potentiated zinc oxide in sheep.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Thirty-six Polypay crossbred wether lambs (33.49 ± 2.81 kg) were used to determine the relative bioavailability of supplemental potentiated zinc oxide (PZO) in comparison to zinc sulfate (ZnSO4) and resulting effects on zinc (Zn) retention, nutrient digestibility, and nitrogen (N) balance. Wethers were sorted by body weight (BW) into three blocks and stagger-started on trial. On d -25 (relative to collection period start), wethers were housed in group pens and began a low-Zn diet (25 mg Zn/kg DM) that was fed for the entirety of the study. Wethers were moved to individual crates on d -10, where they acclimated for 5 d before dietary treatments began on d -5. Zinc treatments were top-dressed using ground corn as a carrier: 1) Control (CON)-no additional Zn supplementation; 2) HiZox® (PZO)-40 mg of supplemented Zn from a potentiated Zn oxide; and 3) Zinc sulfate (ZS) - 40 mg of supplemented Zn from ZnSO4. D 1 began a 5-d total collection period of feces and urine that was utilized for determination of Zn and N retention, as well as dry matter (DM), organic matter (OM), and neutral detergent fiber (NDF) digestibility. Blood was collected on d -5, before starting treatment, and on d 1 and d 5 of the collection period to assess circulating plasma Zn concentrations. Mineral solubility was evaluated, and filtrate Zn content was analyzed. Data were analyzed using the mixed procedure of SAS 9.4 (SAS Institute, Cary, NC). Contrasts compared CON vs. ZINC (PZO and ZS together) and the two Zn sources (PZO vs. ZS). Significance was declared at P ≤ 0.05 and tendencies at 0.05 < P ≤ 0.10. Dietary treatment did not affect DM, OM, or NDF intake, fecal output, or N intake, fecal and urinary output, and retention (mg/d and percent of intake; P ≥ 0.24). Nitrogen retention was greater in wethers supplemented with Zn (P = 0.02). Zinc intake, fecal output, retention (mg/d and percent of intake), and apparent absorption were greater for ZINC compared with CON (P ≤ 0.01) but did not differ between Zn sources (P ≥ 0.44). The inclusion of supplemental Zn improved N apparent absorption (P = 0.02), however, no differences were observed between Zn sources (P = 0.25). The PZO was less soluble in both solutions compared to the ZS (P ≤ 0.01). These data indicate the potentiated Zn oxide has a similar relative bioavailability compared to Zn sulfate and elicited similar effects on diet digestibility and N utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.